Japan’s Shionogi has entered into a new license agreement and research collaboration with US biopharma Hsiri Therapeutics to discover and develop additional novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB).
This new collaboration will include technology that complements Shionogi’s earlier collaboration arrangement with Hsiri.
The new tech to be licensed from Hsiri has a novel mechanism of action, will be complementary to Shionogi’s current research with Hsiri, and is anticipated to be more effective than current therapies for mycobacterial infections.
Shionogi’s strength in small molecule drug discovery and development in the antibacterial area will support development of Hsiri’s innovative therapeutics in this collaborative program.
The agreement means that Shionogi will have exclusive worldwide rights to develop, manufacture, and commercialise the compounds generated from the collaboration.
Hsiri will receive an upfront license fee, potential development milestones, and royalty payments based on sales from Shionogi.